Frova - (EQ 2.5mg Base; Tablet, Oral)

Generic Name	Frovatriptan Succinate	Innovator	Endo Pharma
Dosage	EQ 2.5mg Base; Tablet, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Indicated for the acute treatment of migraine with or without aura in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ **	*** **, ****	******* \**** ** ** ** '*** ******	********	******** ** *** **, ****

Chronology Of Events